Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Anxiety, Asthenia, Body temperature, Chills, Decreased appetite
Clinical narrative: not feeling well; loss of appetite; loss of stamina; taste is off a little; feels depressed; high anxiety; Some symptos are still ongoing are 40 days; Low grade fever/ Patient continues to have persistent fevers of 100.5 degrees fahrenheit; nausea; fatigue; headache; chills; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (not feeling well), DECREASED APPETITE (loss of appetite), ASTHENIA (loss of stamina), TASTE DISORDER (taste is off a little) and DEPRESSED MOOD (feels depressed) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 045A21A and 011A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug allergy, Drug allergy, Postconcussional syndrome (postconcussion syndrome after a closed head injury), Osteoarthritis, Chronic renal insufficiency (chronic renal insufficiency), Fibromyalgia and Diverticulosis. Concomitant products included DESLORATADINE (CLARINEX [DESLORATADINE]) for Allergy, ALPRAZOLAM (XANAX) for Anxiety, BUPROPION HYDROCHLORIDE (WELLBUTRIN) and DULOXETINE HYDROCHLORIDE (CYMBALTA) for Anxiety depression, METHYLPHENIDATE HYDROCHLORIDE (RITALIN) for Depression, FAMOTIDINE (PEPCID [FAMOTIDINE]) for Gastritis, BUTALBITAL, CAFFEINE, PARACETAMOL (FIORICET) for Headache, ROSUVASTATIN CALCIUM (CRESTOR) for High cholesterol, OLMESARTAN MEDOXOMIL (BENICAR) for Hypertension, ONDANSETRON (ZOFRAN [ONDANSETRON]) for Nausea, ROSUVASTATIN, BUPROPION, DULOXETINE, METHYLPHENIDATE and HYDROCHLOROTHIAZIDE, OLMESARTAN MEDOXOMIL (OLMESARTAN + HIDROCLOROTIAZIDA SANDOZ) for an unknown indication.   On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MALAISE (not feeling well), DECREASED APPETITE (loss of appetite), ASTHENIA (loss of stamina), TASTE DISORDER (taste is off a little), DEPRESSED MOOD (feels depressed), ANXIETY (high anxiety), INFUSION RELATED REACTION (Some symptos are still ongoing are 40 days), PYREXIA (Low grade fever/ Patient continues to have persistent fevers of 100.5 degrees fahrenheit), NAUSEA (nausea), FATIGUE (fatigue), HEADACHE (headache) and CHILLS (chills). At the time of the report, MALAISE (not feeling well), DECREASED APPETITE (loss of appetite), ASTHENIA (loss of stamina), TASTE DISORDER (taste is off a little), DEPRESSED MOOD (feels depressed), ANXIETY (high anxiety), INFUSION RELATED REACTION (Some symptos are still ongoing are 40 days), PYREXIA (Low grade fever/ Patient continues to have persistent fevers of 100.5 degrees fahrenheit), NAUSEA (nausea), FATIGUE (fatigue), HEADACHE (headache) and CHILLS (chills) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100.5 (High) 100.5 Fahrenheit, persistent fever. On an unknown date, White blood cell count: increased (High) elevated.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Workup has included a normal CBC, C3, C4, SPEP (except low gamma globulin), CK, TSH, ESR andCRP   Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: follow up received on 26- may-2021, ne w events added, medically confirmed changed to yes On 28-May-2021: Follow up received on 28- May-2021, physician s report received, concomitant medications added On 07-Jul-2021: Follow up received on 07-JUL-2021, Patient Historical conditions and Allergies were added.Concomitant Products were updated.